CompanyGraph
China Resources Double Crane Pharmaceutical Co., Ltd.
600062 · SSE · China
dcpc.comFinancials as of FY2025
Operates as a multi-segment drug maker: finished chronic-disease, specialty and infusion medicines sold as one business, and chemical or biological active pharmaceutical ingredients manufactured and sold as another.
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.5B, above the global median of $1.18B
- FinancialsAltman Z-Score 4.39: safe zone
What this company is and how it runs — written from structure, not news.
This company sits in the middle of its supply chain: a modest number of upstream connections feed it, while it pushes output out through a somewhat larger number of downstream connections. That position is consistent with a manufacturer that both synthesizes chemical and biological compounds and separately formulates finished medicines.
Money comes in through several distinct channels rather than one product line: finished drug sales spanning chronic-disease, specialty and infusion categories, and a separate stream from manufacturing and selling chemical and biological compounds as active pharmaceutical ingredients.
Book value and reported profit have both increased with notable consistency over the multi-year window CompanyGraph tracks, rather than swinging between gains and setbacks, which points to a scale that has built up steadily rather than in sharp jumps.
Its own filings name raw materials, energy and labor as what its production draws on, and its ingredient-manufacturing operations separately depend on the chemical and biological inputs that synthesis, extraction and fermentation require. CompanyGraph also sees a small number of incoming supply connections into the company, without identifying who or which industry sits on the other end of them.
CompanyGraph sees a small number of outgoing connections carrying this company's output onward, but nothing on file identifies who those downstream parties are or how concentrated they might be. The company's own account describes what it produces but does not name its customers.
This company shares its basic operating shape, making drugs and ingredients that must each clear a regulatory approval step, with a large number of other producers CompanyGraph tracks under the same category. On that measure, the shape is common rather than distinctive.
CompanyGraph's classification of this company's industry points to the regulatory approval process that new drugs and ingredients must clear before they can be sold as an ongoing outside pressure on companies in that category. This is a general reading tied to the category the company is classified in, not a company-specific disclosure, since nothing in the company's own account names specific regulators, legal proceedings or trade exposure.
Read from the company's own filings and public materials (gathered August 2026) together with figures CompanyGraph recomputed from its statements. Written September 2026. A question with no evidence behind it is left out rather than answered.
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.